JPT’s peptides continue to contribute to important SARS-CoV-2 publications
Published on 05/11/2021
With several SARS-CoV-2 vaccines approved all over the world, the situation is getting better, but the pandemic is far from over.
In response, we continue to introduce new products for COVID-19 research, such as PepMix™ peptide pools for specific variants of concern or other known coronaviruses. Have a look at our catalog!
Our expertise is directed at the research and development of specific peptides for immunotherapies, vaccines and the accompanying immune monitoring, which has resulted in a variety of COVID-19 specific products. We proudly present some recent high-impact publications describing the use of these peptide products for fighting COVID-19. Have a look!